Centre for Infectious Disease Research in Zambia
Lusaka, Zambia
NCT Number: NCT02459678
This study seeks to evaluate the readiness of HIV-infected pregnant women in Zambia to initiate, adhere to, and be retained in care under the Ministry of Health's Option B+ policy. Under a 3-phased research study the investigators will: (1) conduct formative research regarding readiness to start lifelong ART in the pregnant population; (2) translate the results of formative research into a readiness assessment tool and an enhanced adherence package for pregnant women eligible for Option B+ and (3) conduct an individual randomized trial of the enhanced adherence package.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Lusaka, Zambia
This is qualitative and quantitative research exploring the issues of patient readiness to initiate lifelong ART among HIV-infected pregnant women, as well as ART adherence and retention in HIV care and treatment during pregnancy and after delivery.
The objectives of Phase 1 of the study are as follows:
The objectives of Phase 2 of the study are as follows:
The objectives of Phase 3 of the study are as follows:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
The criteria vary by study phase as follows:
Phase 1
Inclusion criteria
Exclusion criteria
Phase 2
Inclusion criteria
Phase 3
Inclusion criteria
Exclusion criteria
The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
Time frame: Within 30 days of eligibility to begin ART under Option B+ policy
ART eligibility in the setting of Option B+ will generally be either the date of HIV diagnosis for pregnant women newly diagnosed with HIV infection during their antenatal care visit or the date of their first antenatal care visit for known HIV-infected pregnant women who are not already on ART
Time frame: Time of delivery
Outcome of virologic suppression at delivery will be analyzed for differences between the SOC arm and intervention arm.
Time frame: Time from ART eligibility to initiation from enrollment until 6 months post-partum
Time frame: At 6 weeks and 6 months of life
University of North Carolina, Chapel Hill
Other
ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03839212
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Miami, Florida, United States
View Trial DetailsNCT03823209
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cleveland, Ohio, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial DetailsNCT02344680
Acquired Immunodeficiency Syndrome, Adenocarcinoma
Lusaka, Lusaka Province, Zambia
View Trial Details